{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:19Z","timestamp":1790188219041,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,28]]},"DOI":"10.7759\/cureus.24575","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:10:51Z","timestamp":1651209051000},"source":"Crossref","is-referenced-by-count":11,"title":["Stem Cell Therapy for Spinal Cord Injury: A Review of Recent Clinical Trials"],"prefix":"10.7759","author":[{"given":"Emmanouil I","family":"Damianakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis S","family":"Benetos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios Stergios","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Kotroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vlamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon G","family":"Pneumaticos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1310\/sci1901-1","article-title":"Causes of spinal cord injury","volume":"19","author":"Chen Y","year":"2013","unstructured":"Chen Y, Tang Y, Vogel LC, Devivo MJ. Causes of spinal cord injury. Top Spinal Cord Inj Rehabil. 2013, 19:1-8. 10.1310\/sci1901-1","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1179\/2045772314Y.0000000233","article-title":"The changing demographics of traumatic spinal cord injury: an 11-year study of 831 patients","volume":"38","author":"Thompson C","year":"2015","unstructured":"Thompson C, Mutch J, Parent S, Mac-Thiong JM. The changing demographics of traumatic spinal cord injury: an 11-year study of 831 patients. J Spinal Cord Med. 2015, 38:214-23. 10.1179\/2045772314Y.0000000233","journal-title":"J Spinal Cord Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-019-0984-1","article-title":"Modern medical management of spinal cord injury","volume":"19","author":"Karsy M","year":"2019","unstructured":"Karsy M, Hawryluk G. Modern medical management of spinal cord injury. Curr Neurol Neurosci Rep. 2019, 19:65. 10.1007\/s11910-019-0984-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3100962","article-title":"Pharmacological therapy of spinal cord injury during the acute phase","volume":"38","author":"Pointillart V","year":"2000","unstructured":"Pointillart V, Petitjean ME, Wiart L, Vital JM, Lassi\u00e9 P, Thicoip\u00e9 M, Dabadie P. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord. 2000, 38:71-6. 10.1038\/sj.sc.3100962","journal-title":"Spinal Cord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102932","article-title":"Stem cell treatment trials of spinal cord injuries in animals","volume":"238","author":"Farid MF","year":"2021","unstructured":"Farid MF, S Abouelela Y, Rizk H. Stem cell treatment trials of spinal cord injuries in animals. Auton Neurosci. 2021, 238:102932. 10.1016\/j.autneu.2021.102932","journal-title":"Auton Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3171\/FOC.2008.25.11.E2","article-title":"Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon","volume":"25","author":"Rowland JW","year":"2008","unstructured":"Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus. 2008, 25:E2. 10.3171\/FOC.2008.25.11.E2","journal-title":"Neurosurg Focus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101670","article-title":"Neuropathology: the foundation for new treatments in spinal cord injury","volume":"42","author":"Kakulas BA","year":"2004","unstructured":"Kakulas BA. Neuropathology: the foundation for new treatments in spinal cord injury. Spinal Cord. 2004, 42:549-63. 10.1038\/sj.sc.3101670","journal-title":"Spinal Cord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1997.86.3.0483","article-title":"Vascular mechanisms in the pathophysiology of human spinal cord injury","volume":"86","author":"Tator CH","year":"1997","unstructured":"Tator CH, Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg. 1997, 86:483-92. 10.3171\/jns.1997.86.3.0483","journal-title":"J Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-012-8287-4","article-title":"Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects","volume":"46","author":"Karimi-Abdolrezaee S","year":"2012","unstructured":"Karimi-Abdolrezaee S, Billakanti R. Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects. Mol Neurobiol. 2012, 46:251-64. 10.1007\/s12035-012-8287-4","journal-title":"Mol Neurobiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.194710","article-title":"Anti-inflammatory properties of the glial scar","volume":"11","author":"Gesteira TF","year":"2016","unstructured":"Gesteira TF, Coulson-Thomas YM, Coulson-Thomas VJ. Anti-inflammatory properties of the glial scar. Neural Regen Res. 2016, 11:1742-3. 10.4103\/1673-5374.194710","journal-title":"Neural Regen Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-012-1336-5","article-title":"Role of the lesion scar in the response to damage and repair of the central nervous system","volume":"349","author":"Kawano H","year":"2012","unstructured":"Kawano H, Kimura-Kuroda J, Komuta Y, et al.. Role of the lesion scar in the response to damage and repair of the central nervous system. Cell Tissue Res. 2012, 349:169-80. 10.1007\/s00441-012-1336-5","journal-title":"Cell Tissue Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-013-8620-6","article-title":"Phagocytosis of microglia in the central nervous system diseases","volume":"49","author":"Fu R","year":"2014","unstructured":"Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. 2014, 49:1422-34. 10.1007\/s12035-013-8620-6","journal-title":"Mol Neurobiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2017.0011","article-title":"Signaling pathways controlling microglia chemotaxis","volume":"40","author":"Fan Y","year":"2017","unstructured":"Fan Y, Xie L, Chung CY. Signaling pathways controlling microglia chemotaxis. Mol Cells. 2017, 40:163-8. 10.14348\/molcells.2017.0011","journal-title":"Mol Cells"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1670-8","article-title":"Microglia and inflammation: conspiracy, controversy or control?","volume":"71","author":"Fernandes A","year":"2014","unstructured":"Fernandes A, Miller-Fleming L, Pais TF. Microglia and inflammation: conspiracy, controversy or control?. Cell Mol Life Sci. 2014, 71:3969-85. 10.1007\/s00018-014-1670-8","journal-title":"Cell Mol Life Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15327","article-title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","volume":"158","author":"Butler CA","year":"2021","unstructured":"Butler CA, Popescu AS, Kitchener EJ, Allendorf DH, Puigdell\u00edvol M, Brown GC. Microglial phagocytosis of neurons in neurodegeneration, and its regulation. J Neurochem. 2021, 158:621-39. 10.1111\/jnc.15327","journal-title":"J Neurochem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20691","article-title":"Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease","volume":"56","author":"Park JY","year":"2008","unstructured":"Park JY, Paik SR, Jou I, Park SM. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease. Glia. 2008, 56:1215-23. 10.1002\/glia.20691","journal-title":"Glia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.11664","article-title":"Suppression of the onset of myelination extends the permissive period for the functional repair of embryonic spinal cord","volume":"89","author":"Keirstead HS","year":"1992","unstructured":"Keirstead HS, Hasan SJ, Muir GD, Steeves JD. Suppression of the onset of myelination extends the permissive period for the functional repair of embryonic spinal cord. Proc Natl Acad Sci U S A. 1992, 89:11664-8. 10.1073\/pnas.89.24.11664","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1101\/gad.868901","article-title":"Ephrin-B3 is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control","volume":"15","author":"Kullander K","year":"2001","unstructured":"Kullander K, Croll SD, Zimmer M, et al.. Ephrin-B3 is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control. Genes Dev. 2001, 15:877-88. 10.1101\/gad.868901","journal-title":"Genes Dev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(94)90247-x","article-title":"Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth","volume":"13","author":"McKerracher L","year":"1994","unstructured":"McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron. 1994, 13:805-811. 10.1016\/0896-6273(94)90247-x","journal-title":"Neuron"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.23-27-09229.2003","article-title":"The transmembrane semaphorin Sema4D\/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion","volume":"23","author":"Moreau-Fauvarque C","year":"2003","unstructured":"Moreau-Fauvarque C, Kumanogoh A, Camand E, et al.. The transmembrane semaphorin Sema4D\/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci. 2003, 23:9229-39. 10.1523\/jneurosci.23-27-09229.2003","journal-title":"J Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(94)90042-6","article-title":"A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration","volume":"13","author":"Mukhopadhyay G","year":"1994","unstructured":"Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Filbin MT. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron. 1994, 13:757-767. 10.1016\/0896-6273(94)90042-6","journal-title":"Neuron"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v6.i2.120","article-title":"Mesenchymal stem cells in the treatment of spinal cord injuries: A review","volume":"6","author":"Dasari VR","year":"2014","unstructured":"Dasari VR, Veeravalli KK, Dinh DH. Mesenchymal stem cells in the treatment of spinal cord injuries: A review. World J Stem Cells. 2014, 6:120-33. 10.4252\/wjsc.v6.i2.120","journal-title":"World J Stem Cells"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106565","article-title":"Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series","volume":"203","author":"Honmou O","year":"2021","unstructured":"Honmou O, Yamashita T, Morita T, et al.. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021, 203:106565. 10.1016\/j.clineuro.2021.106565","journal-title":"Clin Neurol Neurosurg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.917624","article-title":"Motoric recovery after transplantation of bone marrow derived mesenchymal stem cells in chronic spinal cord injury: a case report","volume":"20","author":"Phedy P","year":"2019","unstructured":"Phedy P, Djaja YP, Gatam L, et al.. Motoric recovery after transplantation of bone marrow derived mesenchymal stem cells in chronic spinal cord injury: a case report. Am J Case Rep. 2019, 20:1299-304. 10.12659\/AJCR.917624","journal-title":"Am J Case Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.03.032","article-title":"Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100\/3 guideline","volume":"20","author":"Vaquero J","year":"2018","unstructured":"Vaquero J, Zurita M, Rico MA, et al.. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100\/3 guideline. Cytotherapy. 2018, 20:806-19. 10.1016\/j.jcyt.2018.03.032","journal-title":"Cytotherapy"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.04.006","article-title":"Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia","volume":"20","author":"Vaquero J","year":"2018","unstructured":"Vaquero J, Zurita M, Rico MA, et al.. Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia. Cytotherapy. 2018, 20:796-805. 10.1016\/j.jcyt.2018.04.006","journal-title":"Cytotherapy"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjy300","article-title":"Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy","volume":"2018","author":"Guadalajara Labajo H","year":"2018","unstructured":"Guadalajara Labajo H, Le\u00f3n Arellano M, Vaquero Crespo J, Valverde N\u00fa\u00f1ez I, Garc\u00eda-Olmo D. Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy. J Surg Case Rep. 2018, 2018:rjy300. 10.1093\/jscr\/rjy300","journal-title":"J Surg Case Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.12.002","article-title":"Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury","volume":"19","author":"Vaquero J","year":"2017","unstructured":"Vaquero J, Zurita M, Rico MA, et al.. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy. 2017, 19:349-59. 10.1016\/j.jcyt.2016.12.002","journal-title":"Cytotherapy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.276340","article-title":"Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury","volume":"15","author":"Deng WS","year":"2020","unstructured":"Deng WS, Ma K, Liang B, et al.. Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury. Neural Regen Res. 2020, 15:1686-700. 10.4103\/1673-5374.276340","journal-title":"Neural Regen Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.09.012","article-title":"Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1\/2 pilot study","volume":"23","author":"Yang Y","year":"2021","unstructured":"Yang Y, Pang M, Du C, et al.. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1\/2 pilot study. Cytotherapy. 2021, 23:57-64. 10.1016\/j.jcyt.2020.09.012","journal-title":"Cytotherapy"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/0963689718766279","article-title":"Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem cells","volume":"27","author":"Xiao Z","year":"2018","unstructured":"Xiao Z, Tang F, Zhao Y, et al.. Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem cells. Cell Transplant. 2018, 27:907-15. 10.1177\/0963689718766279","journal-title":"Cell Transplant"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.08.008","article-title":"Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study","volume":"23","author":"Albu S","year":"2021","unstructured":"Albu S, Kumru H, Coll R, et al.. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021, 23:146-56. 10.1016\/j.jcyt.2020.08.008","journal-title":"Cytotherapy"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1545968320935815","article-title":"The damaged spinal cord is a suitable target for stem cell transplantation","volume":"34","author":"Curt A","year":"2020","unstructured":"Curt A, Hsieh J, Schubert M, et al.. The damaged spinal cord is a suitable target for stem cell transplantation. Neurorehabil Neural Repair. 2020, 34:758-68. 10.1177\/1545968320935815","journal-title":"Neurorehabil Neural Repair"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2018.5843","article-title":"Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury","volume":"36","author":"Levi AD","year":"2019","unstructured":"Levi AD, Anderson KD, Okonkwo DO, et al.. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2019, 36:891-902. 10.1089\/neu.2018.5843","journal-title":"J Neurotrauma"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyx250","article-title":"Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury","volume":"82","author":"Levi AD","year":"2018","unstructured":"Levi AD, Okonkwo DO, Park P, et al.. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018, 82:562-75. 10.1093\/neuros\/nyx250","journal-title":"Neurosurgery"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.05.014","article-title":"A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury","volume":"22","author":"Curtis E","year":"2018","unstructured":"Curtis E, Martin JR, Gabel B, et al.. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell. 2018, 22:941-950.e6. 10.1016\/j.stem.2018.05.014","journal-title":"Cell Stem Cell"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41393-021-00687-5","article-title":"Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury: a clinical trial","volume":"60","author":"Zamani H","year":"2022","unstructured":"Zamani H, Soufizomorrod M, Oraee-Yazdani S, Naviafar D, Akhlaghpasand M, Seddighi A, Soleimani M. Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury: a clinical trial. Spinal Cord. 2022, 60:63-70. 10.1038\/s41393-021-00687-5","journal-title":"Spinal Cord"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2020.7590","article-title":"Phase 1 safety trial of autologous human Schwann cell transplantation in chronic spinal cord injury","volume":"39","author":"Gant KL","year":"2022","unstructured":"Gant KL, Guest JD, Palermo AE, et al.. Phase 1 safety trial of autologous human Schwann cell transplantation in chronic spinal cord injury. J Neurotrauma. 2022, 39:285-99. 10.1089\/neu.2020.7590","journal-title":"J Neurotrauma"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2016.4895","article-title":"Safety of autologous human Schwann cell transplantation in subacute thoracic spinal cord injury","volume":"34","author":"Anderson KD","year":"2017","unstructured":"Anderson KD, Guest JD, Dietrich WD, et al.. Safety of autologous human Schwann cell transplantation in subacute thoracic spinal cord injury. J Neurotrauma. 2017, 34:2950-63. 10.1089\/neu.2016.4895","journal-title":"J Neurotrauma"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2022.02.004","article-title":"Systemic administration of allogeneic cord blood mononuclear cells in adults with severe acute contusion spinal cord injury: phase 1\/2a pilot clinical study-safety and primary efficacy evaluation","author":"Smirnov VA","year":"2022","unstructured":"Smirnov VA, Radaev SM, Morozova YV, et al.. Systemic administration of allogeneic cord blood mononuclear cells in adults with severe acute contusion spinal cord injury: phase 1\/2a pilot clinical study-safety and primary efficacy evaluation. World Neurosurg. 2022, 10.1016\/j.wneu.2022.02.004","journal-title":"World Neurosurg"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112698","article-title":"Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy","volume":"20","author":"Cofano F","year":"2019","unstructured":"Cofano F, Boido M, Monticelli M, Zenga F, Ducati A, Vercelli A, Garbossa D. Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy. Int J Mol Sci. 2019, 20:10.3390\/ijms20112698","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1532\/ijh97.a10404","article-title":"Isolation of mesenchymal stem cells from cryopreserved human umbilical cord blood","volume":"81","author":"Lee MW","year":"2005","unstructured":"Lee MW, Yang MS, Park JS, Kim HC, Kim YJ, Choi J. Isolation of mesenchymal stem cells from cryopreserved human umbilical cord blood. Int J Hematol. 2005, 81:126-30. 10.1532\/ijh97.a10404","journal-title":"Int J Hematol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr063","article-title":"Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke","volume":"134","author":"Honmou O","year":"2011","unstructured":"Honmou O, Houkin K, Matsunaga T, et al.. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 2011, 134:1790-807. 10.1093\/brain\/awr063","journal-title":"Brain"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1357-z","article-title":"Crosstalk between stem cell and spinal cord injury: pathophysiology and treatment strategies","volume":"10","author":"Shao A","year":"2019","unstructured":"Shao A, Tu S, Lu J, Zhang J. Crosstalk between stem cell and spinal cord injury: pathophysiology and treatment strategies. Stem Cell Res Ther. 2019, 10:238. 10.1186\/s13287-019-1357-z","journal-title":"Stem Cell Res Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2013.01.026","article-title":"Neural stem cells in the adult spinal cord","volume":"260","author":"Sabelstr\u00f6m H","year":"2014","unstructured":"Sabelstr\u00f6m H, Stenudd M, Fris\u00e9n J. Neural stem cells in the adult spinal cord. Exp Neurol. 2014, 260:44-9. 10.1016\/j.expneurol.2013.01.026","journal-title":"Exp Neurol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903585290","article-title":"Efficient differentiation of human embryonic stem cells into oligodendrocyte progenitors for application in a rat contusion model of spinal cord injury","volume":"120","author":"Kerr CL","year":"2010","unstructured":"Kerr CL, Letzen BS, Hill CM, et al.. Efficient differentiation of human embryonic stem cells into oligodendrocyte progenitors for application in a rat contusion model of spinal cord injury. Int J Neurosci. 2010, 120:305-13. 10.3109\/00207450903585290","journal-title":"Int J Neurosci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/nn1405","article-title":"Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome","volume":"8","author":"Hofstetter CP","year":"2005","unstructured":"Hofstetter CP, Holmstr\u00f6m NA, Lilja JA, et al.. Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci. 2005, 8:346-53. 10.1038\/nn1405","journal-title":"Nat Neurosci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.128212","article-title":"Bridging the injured spinal cord with neural stem cells","volume":"9","author":"Dulin JN","year":"2014","unstructured":"Dulin JN, Lu P. Bridging the injured spinal cord with neural stem cells. Neural Regen Res. 2014, 9:229-31. 10.4103\/1673-5374.128212","journal-title":"Neural Regen Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2927","article-title":"Role of endogenous neural stem cells in spinal cord injury and repair","volume":"72","author":"Stenudd M","year":"2015","unstructured":"Stenudd M, Sabelstr\u00f6m H, Fris\u00e9n J. Role of endogenous neural stem cells in spinal cord injury and repair. JAMA Neurol. 2015, 72:235-7. 10.1001\/jamaneurol.2014.2927","journal-title":"JAMA Neurol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3171\/2013.3.PEDS12397","article-title":"Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis","volume":"11","author":"Selden NR","year":"2013","unstructured":"Selden NR, Al-Uzri A, Huhn SL, et al.. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr. 2013, 11:643-52. 10.3171\/2013.3.PEDS12397","journal-title":"J Neurosurg Pediatr"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004373","article-title":"Neural stem cell engraftment and myelination in the human brain","volume":"4","author":"Gupta N","year":"2012","unstructured":"Gupta N, Henry RG, Strober J, et al.. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012, 4:155ra137. 10.1126\/scitranslmed.3004373","journal-title":"Sci Transl Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyaa149","article-title":"Cell therapies for spinal cord injury: trends and challenges of current clinical trials","volume":"87","author":"Bartlett RD","year":"2020","unstructured":"Bartlett RD, Burley S, Ip M, Phillips JB, Choi D. Cell therapies for spinal cord injury: trends and challenges of current clinical trials. Neurosurgery. 2020, 87:E456-72. 10.1093\/neuros\/nyaa149","journal-title":"Neurosurgery"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.07.009","article-title":"Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance","volume":"79","author":"Kim YJ","year":"2011","unstructured":"Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol. 2011, 79:112-26. 10.1016\/j.critrevonc.2010.07.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-010-9163-0","article-title":"Transplantation of umbilical cord blood stem cells for treating spinal cord injury","volume":"7","author":"Park DH","year":"2011","unstructured":"Park DH, Lee JH, Borlongan CV, Sanberg PR, Chung YG, Cho TH. Transplantation of umbilical cord blood stem cells for treating spinal cord injury. Stem Cell Rev Rep. 2011, 7:181-94. 10.1007\/s12015-010-9163-0","journal-title":"Stem Cell Rev Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95571-stem-cell-therapy-for-spinal-cord-injury-a-review-of-recent-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:40Z","timestamp":1707507520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95571-stem-cell-therapy-for-spinal-cord-injury-a-review-of-recent-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.24575","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}